Drug and Cosmetic Act + Beauty and Wellness Meta Ads in India

A face serum that ‘brightens’ is a cosmetic. A face serum that ‘treats hyperpigmentation’ is a drug under Indian law. The difference is a single verb — and it controls whether your Meta ad gets approved, your CDSCO compliance holds, and whether you can ever scale that SKU.

Beauty and wellness D2C brands sit in the narrowest regulatory corridor in Indian advertising. The Drugs and Cosmetics Act 1940, the Drugs and Magic Remedies Act 1954, ASCI, CDSCO, and Meta’s India ad review queue all read the same words and draw different lines. Walking that corridor cleanly is what separates the brands that scale to ₹100 crore from the ones that hit a wall at ₹10 crore.

The Cosmetic-Drug Boundary in Indian Law

Section 3(b) of the Drugs and Cosmetics Act 1940 defines a drug as anything used ‘for or in the diagnosis, treatment, mitigation or prevention of any disease or disorder’. Section 3(aaa) defines a cosmetic as anything ‘applied to the human body for cleansing, beautifying, promoting attractiveness, or altering appearance’.

Every claim in your Meta ad gets read against these definitions. A surprisingly long list of common D2C copy lines tips a cosmetic SKU into ‘drug’ territory — and triggers requirements you cannot legally meet without CDSCO licensing.

Claims That Push a Cosmetic Into Drug Territory

The verbs and outcomes below quietly reclassify your product. Each one would require a CDSCO manufacturing licence and clinical substantiation that almost no D2C brand actually holds:

1. ‘Treats’ anything — acne, eczema, dandruff, hair fall, pigmentation, rashes.

2. ‘Cures’ or ‘heals’ — instantly drug-class regardless of the condition.

3. ‘Reduces inflammation’ — therapeutic claim, drug-class.

4. ‘Prevents’ a named condition — even ‘prevents hair fall’ has been challenged.

5. ‘Anti-fungal’, ‘anti-bacterial’, ‘anti-microbial’ with a specific condition.

6. ‘Restores’ something the body lost — bone density, collagen depth.

7. Number-led therapeutic claims — ‘90% reduction in acne in 21 days’.

8. Disease-named hashtags — #pcos #thyroid #diabetes attached to a supplement.

9. Before/after with medical condition labels — labelled ‘before acne / after cure’.

10. Implicit drug references in the visual — pills, syringes, doctor coats.

Safe Cosmetic-Language Equivalents

The same SKU can be advertised compliantly with a vocabulary swap. The conversion rate difference is smaller than founders expect.

• ‘Treats acne’ → ‘helps with the look of blemish-prone skin’.

• ‘Cures dandruff’ → ‘helps reduce visible flakes’.

• ‘Anti-inflammatory’ → ‘soothes the look of irritated skin’.

• ‘Restores collagen’ → ‘supports firmer-looking skin’.

• ‘Reduces hair fall by 87%’ → ‘stronger-looking strands in our consumer study’ — with the study available.

The Drugs and Magic Remedies Act Trap

The Drugs and Magic Remedies (Objectionable Advertisements) Act 1954 is a separate statute and it is the one most D2C wellness brands quietly violate. It prohibits advertising claims to treat or cure 54 listed conditions including diabetes, obesity, sexual disorders, hair loss, skin diseases, and gynaecological complaints — regardless of whether the product is a registered drug.

Practical implication: even if your ‘weight management supplement’ is sold as a food product or nutraceutical, advertising it as helping with obesity is a violation. Same with hair-fall claims tied to a hair oil, or sexual-wellness language tied to an ayurvedic blend.

Meta India Moderation Patterns

Meta’s India ad review queue has tightened on beauty and wellness in 2024-2026. The signals that trip moderation:

• Therapeutic verbs — ‘treat’, ‘cure’, ‘heal’, ‘prevent’ — across the creative and primary text.

• Before-after imagery with medical-condition labels.

• Microscope, lab-coat, or clinical-setting visuals without registered medical-establishment context.

• Percentage claims without an accessible study link.

• DM-pull copy patterns that move sensitive claims off-platform (‘DM us for the real cure’).

The downstream effect of repeated rejections is the worst-kept secret in Indian beauty D2C: account-level moderation scores degrade, ad sets get knocked back to learning, and your best-performing creative ages out before it should. Read our [ad fatigue detection guide](https://www.wittelsbach.ai/post/how-to-detect-ad-fatigue-and-stop-it-before-it-costs-you) for the operational rhythm to handle the resulting creative churn.

The Substantiation File Every Beauty D2C Should Maintain

If you choose to make any number-led claim — even a compliant one — keep a substantiation file ready. ASCI proceedings are won and lost on what you can pull out within 14 days.

• Consumer study protocol — panel size, duration, methodology, ethics clearance.

• Raw study data — anonymised but verifiable.

• Independent lab reports for any active ingredient claim.

• Manufacturer COA for every batch.

• Internal sign-off log — who approved the claim, when, and against what evidence.

Wellness Supplements — The Tightest Category

Nutraceuticals and Ayush products carry the heaviest restrictions. The FSSAI Nutraceutical Regulations 2022, the Ayush Ministry advisories, and the Drugs and Magic Remedies Act stack on top of the Drugs and Cosmetics Act. Compliant copy for this category is closer to ‘supports general wellness’ than to anything specific.

Indian wellness D2C brands that have scaled past ₹50 crore in 2024-2026 (Wellbeing Nutrition, OZiva, The Whole Truth, Setu) all run a tight compliance review on every creative before launch. The cost of one CDSCO notice is higher than three months of compliance overhead.

How Wittelsbach AI Pre-Screens Beauty and Wellness Creative

Bach AI applies a beauty and wellness compliance fingerprint trained on Indian regulatory patterns. Every creative is scored before launch on cosmetic/drug boundary, DMR Act risk, and Meta India moderation likelihood — with concrete safe rewrites attached. Try Bach AI on your account at [app.wittelsbach.ai](https://app.wittelsbach.ai).

Frequently Asked Questions

Is ‘clinically tested’ a safe phrase in Indian beauty ads?

Only if the test exists, the protocol is documented, and the test was run on the finished product (not just the active ingredient). ASCI specifically pulls up brands that cite ingredient-level studies as if they were product-level evidence. ‘Clinically tested’ without a real study file is one of the most-flagged claims in India in 2026.

Can I use a doctor in my Meta ad creative?

Generally no for cosmetics and nutraceuticals. Section 6 of the Indian Medical Council professional conduct regulations prohibits doctors from endorsing branded products. Meta India also flags lab-coat imagery as a therapeutic-claim signal. The compliant alternative: cite peer-reviewed research generically and disclose any consultant relationships.

Are ayurvedic claims treated differently from cosmetic claims?

Yes, but not in the way founders expect. Ayurvedic products fall under the Ayush Ministry plus the Drugs and Cosmetics Act, and DMR Act restrictions still apply. ‘Traditional usage’ language is permitted, but specific disease claims are not. Saying ‘traditionally used for digestion’ is fine, ‘cures IBS’ is not.

What if my international parent brand makes stronger claims abroad?

Foreign parent claims carry zero weight in Indian advertising compliance. Several global beauty brands have learned this through ASCI proceedings: the EU/US claim file does not substitute for an India-compliant claim. Every market needs its own substantiation under its own legal framework.

Does ‘ayurvedic’ on the label exempt me from Drugs and Magic Remedies Act restrictions?

No. The DMR Act applies to advertisements regardless of the regulatory category of the product. An ayurvedic product cannot advertise to cure obesity, diabetes, hair loss, or any of the 54 listed conditions. Selling the product is legal — advertising specific cures for those conditions is not.